• 0662T  -- Scalp cooling, mechanical; initial measurement and calibration of cap (once per chemotherapy treatment period)
• 0663T  -- Placement of scalp cooling device, monitoring, and removal (once per chemotherapy session)

The availability of CPT codes provides a pathway to insurance reimbursement that will then increase patient access to scalp cooling treatments.

In the fourth quarter the European Society for Medical Oncology (ESMO) updated their Clinical Practice Guidelines (https://www.annalsofoncology.org/article/S0923-7534(20)43157-6/fulltext) to include the recommendation of scalp cooling for the prevention of chemotherapy-induced alopecia as a Category IIB treatment recommendation. A multidisciplinary group of oncology experts from Europe, the United States and Australia authored the recommendation. The ESMO recommendation is similar to those published by Cancer Australia earlier this fall in the Guidance for the management of early breast cancer patients (https://www.guidancebreastcancer.gov.au/sites/default/files/guidelines/GEBC_Recommendations%20and%20practice%20points_Pdf_Sept%202020.pdf). Additionally, in United States the National Comprehensive Cancer Network® (NCCN) added scalp cooling to their annual guidelines as a Class 2A recommendation for patients with breast cancer in 2019 and ovarian cancer in 2020. These guidelines are widely recognized as the benchmark for oncology treatment coverage and reimbursement by clinicians and payers.

"As we enter the new year we have incredible opportunities ahead of us around the globe. The introduction of CPT codes this year will remove financial barriers in the U.S. and allow us to help more patients. In addition the recommendations from ESMO, Cancer Australia and NCCN are meaningful endorsements of our scalp cooling therapy to the medical community. We value their support as we continue with our plan of accelerated growth," said William Cronin, Dignitana CEO.